[go: up one dir, main page]

MX2017010628A - Proteinas especificas novedosas para pioverdina y pioquelina. - Google Patents

Proteinas especificas novedosas para pioverdina y pioquelina.

Info

Publication number
MX2017010628A
MX2017010628A MX2017010628A MX2017010628A MX2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A MX 2017010628 A MX2017010628 A MX 2017010628A
Authority
MX
Mexico
Prior art keywords
muteins
present description
pioverdine
pioqueline
specific proteins
Prior art date
Application number
MX2017010628A
Other languages
English (en)
Other versions
MX375049B (es
Inventor
Corvey Carsten
Kruip Jochen
Rey Astrid
Fraisse Laurent
Rothe Christine
Hinner Marlon
Lunde Bradley
Wiedenmann Alexander
Stump Heike
Calandra Bernhard
Karst Nathalie
Mourez Michael
Allersdorfer Andrea
Jensen Kristian
Hülsmeyer Martin
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2017010628A publication Critical patent/MX2017010628A/es
Publication of MX375049B publication Critical patent/MX375049B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente descripción proporciona muteínas de hNGAL a las que se une un miembro de la familia de pioverdina o pioquelina y que se pueden usar en diversas aplicaciones incluyendo aplicaciones farmacéuticas, por ejemplo, para inhibir o reducir el crecimiento de P. aeruginosa. La presente descripción también se refiere a métodos para preparar una o más muteínas a las que se une pioverdina o pioquelina descritas en la presente descripción, así como a composiciones que comprenden una o más de dichas muteínas. La presente descripción se refiere además a moléculas de ácido nucleico que codifican dichas muteínas y a métodos para la generación de dichas muteínas y moléculas de ácido nucleico. Además, la solicitud describe usos terapéuticos y/o de diagnóstico de estas muteínas así como composiciones que comprenden o más de dichas muteínas.
MX2017010628A 2015-02-18 2016-02-16 Proteinas especificas novedosas para pioverdina y pioquelina. MX375049B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15305242 2015-02-18
PCT/EP2016/053226 WO2016131804A1 (en) 2015-02-18 2016-02-16 Novel proteins specific for pyoverdine and pyochelin

Publications (2)

Publication Number Publication Date
MX2017010628A true MX2017010628A (es) 2017-12-07
MX375049B MX375049B (es) 2025-03-06

Family

ID=52595246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017010628A MX375049B (es) 2015-02-18 2016-02-16 Proteinas especificas novedosas para pioverdina y pioquelina.

Country Status (28)

Country Link
US (8) US9884898B2 (es)
EP (1) EP3259282A1 (es)
JP (1) JP6843754B2 (es)
KR (1) KR20170116158A (es)
CN (1) CN107660211A (es)
AR (1) AR103714A1 (es)
AU (1) AU2016221816B2 (es)
BR (1) BR112017017530A2 (es)
CA (1) CA2976687A1 (es)
CL (1) CL2017002082A1 (es)
CO (1) CO2017009433A2 (es)
CR (1) CR20170425A (es)
DO (1) DOP2017000191A (es)
EA (1) EA035824B1 (es)
EC (1) ECSP17061751A (es)
GT (1) GT201700184A (es)
HK (1) HK1245293A1 (es)
IL (1) IL254013A0 (es)
MA (1) MA41072A1 (es)
MX (1) MX375049B (es)
PE (1) PE20171652A1 (es)
PH (1) PH12017501473A1 (es)
SG (1) SG11201706621SA (es)
TN (1) TN2017000348A1 (es)
TW (1) TW201636364A (es)
UY (1) UY36561A (es)
WO (1) WO2016131804A1 (es)
ZA (1) ZA201705257B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2510357B1 (en) 2009-12-07 2016-03-30 Pieris AG Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
CN106573964B (zh) 2014-05-22 2021-07-16 皮里斯制药有限公司 新型特异性结合多肽及其用途
KR20170105609A (ko) 2015-01-28 2017-09-19 피어이스 파마슈티컬즈 게엠베하 신생혈관형성에 특이적인 신규한 단백질
EA035824B1 (ru) * 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
EP3292137B1 (en) 2015-05-04 2022-09-07 Pieris Pharmaceuticals GmbH Proteins specific for cd137
JP6783797B2 (ja) 2015-05-04 2020-11-11 ピエリス ファーマシューティカルズ ゲーエムベーハー 抗がん融合ポリペプチド
SMT202300026T1 (it) 2015-05-18 2023-03-17 Pieris Pharmaceuticals Gmbh Polipeptide di fusione anti-cancro
CA2982034A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
CN108699162A (zh) 2015-11-30 2018-10-23 皮里斯澳大利亚有限公司 新型抗血管生成融合多肽
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
EP3823667A4 (en) * 2018-07-19 2022-07-27 The Regents Of The University Of Colorado Methods, systems and compositions for the novel use of enterobactin to treat iron deficiency and related anemia
CN113939307A (zh) 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CN116077621A (zh) * 2021-11-05 2023-05-09 华南农业大学 P19蛋白在调控绿脓杆菌毒力中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
RS50144B (sr) 1998-06-08 2009-03-25 F. Hoffmann-La Roche Ag., Primena peg-inf-alfa 2a i ribavirina za proizvodnju leka za lečenje hroničnog hepatitisa c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) * 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
ES2667066T3 (es) * 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
WO2014076321A1 (en) 2012-11-19 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
EA035824B1 (ru) * 2015-02-18 2020-08-17 Пайерис Фармасьютикалс Гмбх Новые белки, специфичные к пиовердину и пиохелину
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
US20180030101A1 (en) 2018-02-01
CN107660211A (zh) 2018-02-02
CR20170425A (es) 2017-11-22
TN2017000348A1 (en) 2019-01-16
WO2016131804A1 (en) 2016-08-25
ECSP17061751A (es) 2017-10-31
EA201791841A1 (ru) 2018-01-31
JP6843754B2 (ja) 2021-03-17
HK1245293A1 (zh) 2018-08-24
GT201700184A (es) 2018-10-24
SG11201706621SA (en) 2017-09-28
JP2018506979A (ja) 2018-03-15
EA035824B1 (ru) 2020-08-17
MA41072A1 (fr) 2018-10-31
PE20171652A1 (es) 2017-11-13
US20180037618A1 (en) 2018-02-08
MX375049B (es) 2025-03-06
ZA201705257B (en) 2019-06-26
TW201636364A (zh) 2016-10-16
US20180371038A1 (en) 2018-12-27
DOP2017000191A (es) 2017-09-29
PH12017501473A1 (en) 2018-01-29
US20170267734A1 (en) 2017-09-21
US10065998B2 (en) 2018-09-04
CL2017002082A1 (es) 2018-04-27
CO2017009433A2 (es) 2017-11-30
UY36561A (es) 2016-09-30
AU2016221816A1 (en) 2017-10-12
AR103714A1 (es) 2017-05-31
CA2976687A1 (en) 2016-08-25
US20180037619A1 (en) 2018-02-08
US20180086799A1 (en) 2018-03-29
US20180371037A1 (en) 2018-12-27
US10329334B2 (en) 2019-06-25
US9884898B2 (en) 2018-02-06
EP3259282A1 (en) 2017-12-27
IL254013A0 (en) 2017-10-31
US10072056B2 (en) 2018-09-11
AU2016221816B2 (en) 2020-07-02
KR20170116158A (ko) 2017-10-18
US20180346532A1 (en) 2018-12-06
US10118952B2 (en) 2018-11-06
BR112017017530A2 (pt) 2018-04-17

Similar Documents

Publication Publication Date Title
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2017002650A1 (es) Compuestos novedosos
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX385926B (es) Proteínas de fusión de citoquinas.
MX2021000401A (es) Nuevas proteinas de fusion especificas para cd137 y pd-l1.
DOP2016000253A (es) Nuevos compuestos
UY36157A (es) Composiciones pesticidas y procedimientos relacionados con las mismas
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
DOP2018000049A (es) Compuestos para uso en aplicaciones antibacterianas
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
ECSP18008488A (es) Moléculas de fusión
CR20160432A (es) Inhibidores de las vías de señalización de wnt
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino
AR115878A1 (es) Proteínas de fusión específicas para cd137 y pd-l1
BR112017027567A2 (pt) proteínas de fusão para inibir a angiogênese

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: PIERIS PHARMACEUTICALS GMBH

FG Grant or registration